Current Clinical Trials

COMBINE 2 is a 52-week study comparing the efficacy and safety of once weekly IcoSema (weekly insulin Icodec combined with weekly semaglutide) and once weekly semaglutide, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist. The main purpose of the study is to see how well the investigational medicine IcoSema controls blood sugar levels in people with type 2 diabetes. This will be assessed by examining the change in A1c (3 month blood sugar average) throughout the study. Approximately 680 men and women across the world will take part in this study. The information collected during the study may also help us better understand type 2 diabetes or related diseases, how the study medicine works in the body, and how to improve the treatment of people with type 2 diabetes or related diseases.

PROMISE is a 15 year observational (no study medication) study of approximately 800-1000 individuals age 30 and older (18 and older for Aboriginal subjects) at high risk for glucose intolerance. After the 15 year study period, there will be long term follow up through record linkage to the Canadian Institute of Health Information and the Statistics Canada vital statistics databases, both of which are standard methods for determining whether hospitalizations or deaths have occurred among participants. The overall objective of the PROMISE study is to understand the determinants of obesity, impaired fasting glucose, impaired glucose tolerance, T2DM and associated metabolic abnormalities, including insulin resistance, beta cell dysfunction and microalbuminuria.